<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref86">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lim</surname>
    <given-names>J. J.</given-names>
   </name>
   <name>
    <surname>Deng</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Derby</surname>
    <given-names>M. A.</given-names>
   </name>
   <name>
    <surname>Larouche</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Horn</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Anderson</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2016</year>). 
  <article-title>Two phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza A virus monoclonal antibody, MHAA4549A, in healthy volunteers</article-title>. 
  <source>Antimicrob. Agents Chemother.</source>
  <volume>60</volume>, 
  <fpage>5437</fpage>â€“
  <lpage>5444</lpage>. 
  <pub-id pub-id-type="doi">10.1128/AAC.00607-16</pub-id>, PMID: 
  <?supplied-pmid 27381392?>
  <pub-id pub-id-type="pmid">27381392</pub-id>
 </mixed-citation>
</ref>
